Clinical Trials in Detroit

Showing 6941-6960 of 19,719 trials

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT04159896

This phase II trial studies the side effects of ESK981 and nivolumab and to see how well they work for the treatment of castration resistant prostate cancer that has spread to other places in the body (metastatic). ESK981 is an investigational drug that targets several important pathways that are believed to play a role in the spread of cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to see if giving ESK981 and nivolumab together works better in treating metastatic castration resistant prostate cancer compared to usual treatments.

Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+2 more

Barbara Ann Karmanos Cancer Institute10 participantsStarted Nov 2019

Ann Arbor, Michigan, United States • Detroit, Michigan, United States

RECRUITINGPhase 1/2< 1 mile

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

NCT05271292

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.

Small Cell Lung CancerAdvanced Solid Malignant Tumor

Chipscreen Biosciences, Ltd.36 participantsStarted Aug 2022

Encinitas, California, United States • Fullerton, California, United States • Atlanta, Georgia, United States +8 more locations

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Find Trials by Condition in Detroit

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Belimumab Assessment of Safety in SLE

A Study to Evaluate in Patients With Parkinsonian Type Disorders

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Treatment of Gingival Recession Defects Using Platelet-Rich Fibrin With an Allogenic Dermal Matrix

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

C-myc Biomarker Study for Diabetic Foot Ulcers

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis

Design Validation of Toric Contact Lenses in Senofilcon A With a Blue-Blocking Chromophore

Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Impact of Microvascular Inflammation on Kidney Allograft Outcome

Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma